Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04685226 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jun 2025 to Jan 25, 2028 Completion date: Feb 2028 to Feb 25, 2028v5 Show 1 more changeShow less
    • Completion date: Feb 2028 to Feb 25, 2028
  2. Enrollment target: 42 to 310 Primary completion date: Dec 27, 2022 to Jun 2025 · Study sites: 9 to 24 · Completion date: Dec 30, 2022 to Feb 2028v4 Show 3 more changesShow less
    • Primary completion date: Dec 27, 2022 to Jun 2025
    • Study sites: 9 to 24
    • Completion date: Dec 30, 2022 to Feb 2028
  3. Study sites: 2 to 9 Eligibility criteria shortened, about 15 wordsv3 Show 1 more changeShow less
    • Eligibility criteria shortened, about 15 words

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors
Trial Details
NCT Number NCT04685226
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Solid Tumors
Enrollment 310 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov